+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 75Years
All Genders
ID07647094

Efficacy and Safety Study of Low-Dose Carboplatin with Nab-Paclitaxel and Delayed Serplulimab for Advanced Squamous Non-Small Cell Lung Cancer

Led by People's Hospital of Quzhou · Updated on 2026-09-25

112

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of a low-dose chemotherapy combined with delayed use of Serplulimab as the first treatment for people with advanced or metastatic squamous non-small cell lung cancer NSCLC whose gene status is unknown or negative. This phase 2, multicenter randomized controlled trial compares two dosing regimens of carboplatin and Nab-Paclitaxel chemotherapy with Serplulimab. The study is designed to better understand treatment options for this specific type of lung cancer. Participants are randomly assigned to one of two groups a low dose group receiving Nab-Paclitaxel 195 mgm and carboplatin AUC3.75 every three weeks with Serplulimab given on the third day, or a standard dose group receiving Nab-Paclitaxel 260 mgm and carboplatin AUC5 with Serplulimab on the first day of each cycle. Each cycle lasts three weeks. Treatments are given intravenously and continue over multiple cycles as determined by the study protocol. During the study, participants undergo regular evaluations including imaging to measure tumor response and scans to assess disease progression. Researchers monitor safety by tracking adverse events and treatment tolerability over 36 months. The primary outcome is the objective response rate, with secondary outcomes including progression-free survival, disease control rate, duration of remission, overall survival, and incidence of adverse events. The total participation time spans from treatment initiation through long-term follow-up to assess effectiveness and safety.

CONDITIONS

Brief Title

A Prospective, Multicenter, Randomized Controlled Study on the Efficacy and Safety of Low-dose Carboplatin Combined With Nab-Paclitaxel and Delayed Administration of Serplulimab as First-line Treatment for Advanced Squamous Non-small Cell Lung Cancer

Research Team

X

Xuru Jin

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here